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Statement of Translational Relevance
DNA repair processes, which are defective in many cancer cells, offer avenues for therapeutic intervention. Thus, preclinical/clinical development of non-toxic chemo preventive agents that can selectively induce DNA damage in cancer cells is highly desirable. Supporting this rationale, results of the present study are highly significant with major implications where we report that the anti-cancer effect of resveratrol is predominately due to its ability to induce DNA damage selectively in HNSCC cells without affecting normal, repair-proficient cells. This study reports that resveratrol causes 
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most frequent cancer worldwide and the five-year survival rates are among the lowest (< 60%) of the major cancers.
HNSCC are mainly caused by alcohol consumption, tobacco intake (smoking and smokeless products such as betel quid), poor oral hygiene and infection to high-risk types of human papilloma virus (1) . According to the statistical estimates given by the American Cancer Society, ∼73,080 new cases of HNSCC would have been diagnosed in the United States in the year 2010 (2) . In spite of advancements in surgical procedures, chemotherapy, radiation therapy, as well as combination of these, the patient survival rates have not improved in the last several decades. Moreover, it has been shown that the high rate of morbidity is due to both locoregional recurrence and distant metastasis (1, 3) .
Transforming growth factor-β receptor II (TGF-βRII) is the main pathways that is deregulated in HNSCC (4) where aberrant signaling downstream of this receptor contributes to tumor growth. TGF-β regulates its pleiotropic biological activities through a complex formation between TGF-β receptor type I (TGF-βRI) and type II (TGF-βRII). TGF-β receptors then transmit signal through the activation of the downstream Smad signaling pathways which consists of the Smad family of proteins (Smad1-5) (4). Receptor activated Smads (Smad2 and -3 or Smad1 and -5) associate with Smad4 and form a hetero-oligomeric complex, which translocates to the nucleus where it activates transcription of various target genes namely p53, cyclin dependent kinase inhibitors, c-Myc and those regulating apoptosis (5-7). Mutation in TGF-βRII causes deregulation in growth inhibitory control and tumorigenesis (4 where Smad4 loss caused defects in Fanconi anemia/Brca (Fanc/Brca) pathway leading to genomic instability in mice and spontaneous HNSCC (8) . These observations suggest that agents are needed which could target TGF-β/Smad4 pathway for HNSCC treatment Resveratrol, a nontoxic polyphenolic phytoalexin found in grapes skin, red wine, peanuts, berries, etc, has shown strong efficacy against various cancers in both in vitro and in vivo studies (9, 10) . Recently, a number of interventional clinical trials in humans have been initiated using resveratrol as a therapeutic, oral compound (11) . The voluminous literature regarding anti-cancer efficacy of resveratrol is based on an initial study by Pezzuto and colleagues showing that resveratrol inhibits preneoplastic lesions in carcinogen-treated mouse mammary glands in culture and DMBA-induced skin tumorigenesis in a mouse model (12) . Despite extensive studies with resveratrol in various models and organ sites of malignancies, to date nothing is known about the anti-cancer efficacy of resveratrol against HNSCC. Because of these issues, we assessed whether resveratrol is effective against HNSCC and if resveratrol's efficacy is dependent on Smad4, a key signaling pathway deregulated in HNSCC.
Materials and Methods
Cell culture and reagents
Human HNSCC FaDu, Cal27 and Det562 cells were from ATCC (Manassas, VA) in 2006 and were confirmed by DNA fingerprinting using the ABI Identifiler kit using the following identifiler loci: D3S158, vWA, FGA, Amelogenin, D8S1179, D21S11, D18S51, D13S317, D7S820, CSF1PO, D16S539, THO1, TPOX, D2S1338 and Stable transfectants were selected using G418 at 0.2 mg/ml in DMEM (10% FBS) for 4 weeks, and cells were pooled and maintained in the same selective medium.
MTT assay
Cells were plated in 96 well plate under standard culture conditions, next day treated with resveratrol, and at the end of desired treatment time, 20 μl MTT stock solution (5 mg/ml) was added to each well and incubated for another 5 h. Thereafter, media was aspirated, 200 μl of DMSO added to each well, and absorbance was measured at 570 nm. 
Cell cycle distribution and apoptosis analyses
Cells were treated with resveratrol, trypsinized and washed twice with ice-cold PBS, and pellets were incubated in 0.5 ml of saponin/propidium iodide (PI) solution at 4°C for 24 h in dark as reported earlier (13) . Alternatively, cells were subjected to Annexin V and PI staining using Vybrant Apoptosis Assay Kit 2 following vendor' protocol. Stained cells were analyzed by flow cytometry using the FACS Analysis Core of the UCCC, for cell cycle distribution and apoptotic cell populations, respectively.
Immunoblotting
At 60-65% confluency, cells were treated with resveratrol, cell lysates prepared, 30-60 μg protein per sample denatured with 2X sample buffer and subjected to SDS-PAGE on 12 or 16% gel, and 8 separated proteins were transferred onto membrane by Western blotting as described (13) .
Membranes were blocked with blocking buffer for 1 h at room temperature and probed with primary antibody over night at 4 ο C followed by incubation with peroxidase-conjugated appropriate secondary antibody and ECL detection.
Immunofluorescence staining and confocal microscopy
Cells were plated on cover slips overnight and following desired treatment, washed gently with PBS, fixed in 4% formaldehyde for 15 min, incubated with ice cold 100% methanol for 10 min and 9 CMC and 50 mg/kg resveratrol dose in CMC for 5 days/week for 15 days, respectively. Xenograft growth was measured twice weekly in all groups of animals after 7th day of cells implantation with a digital caliper, and tumor volume calculated as reported recently (14) . Body weight and diet consumption were recorded twice weekly throughout study. At experiment terminations, tumors were excised, weighed and stored at -80°C. Animal care and experiments were in accordance with UCD-approved IACUC protocol.
Immunohistochemical staining
Tumor tissues, fixed in 10% phosphate-buffered formalin for 12 h at 4°C, were dehydrated in ascending concentrations of ethanol, cleared with xylene, embedded in paraffin, and tissue blocks were cut with a rotary microtome into 4-μm sections and processed for immunohistochemical (IHC) staining. Briefly, sections after deparaffinization and re-hydration were treated with 0.01M citrate buffer (pH 6.0) in a microwave for 30 min for antigen-retrieval followed by quenching of endogenous peroxidase activity with 3% H 2 O 2 in methanol (v/v) for 5 min. Next, sections were incubated with specific antibodies, γH2AX and cleaved caspase-3, in PBS for 2 h at room temperature followed by overnight incubation at 4°C in a humidified chamber. Negative controls were incubated only with universal negative control antibodies under identical conditions. Sections 
Statistical analysis
Statistical significance of differences between control and treated samples was determined using Student's t-test (SigmaStat 3.5). P values of <0.05 were considered significant. The data in all cases are representative of at least 2-4 independent studies with reproducible results.
Results
Resveratrol inhibits cell viability and induces DNA damage selectively in HNSCC cells
First we evaluated resveratrol efficacy in a panel of human HNSCC cell lines, namely FaDu (homologous deletion of Smad4), Cal27 (nonsense mutation in Smad4) and Det562 (wild type Smad4) cells. Resveratrol at 50 μM dose caused 83% (p<0.001) and 63% (p<0.001) decrease in viability of FaDu cells after 48 and 72 h, respectively (Fig.1A) . Cal27 cells at 50 μM resveratrol dose also showed up to 43% (p<0.001) decrease in viability (Fig. 1A) ; however, such resveratrol treatments were not effective in Det562 cells, until a higher dose (100 μM) and longer treatment of the agent (Fig.1A) . Several recent studies have shown that natural chemopreventive agents cause DNA damage in tumorigenic cells leading to apoptotic cell death (9) , and accordingly, next we assessed resveratrol effect on DNA damage in HNSCC cells employing the alkaline comet assay.
Compared to controls where DNA remained within the nucleus, in resveratrol-treated cells, damaged DNA exited nucleus and stained as a tail (Fig. 1B) . Overall, Comet assay results clearly showed DNA-damaged FaDu and Cal27 cells following resveratrol treatment; however, Det562 cells had less DNA damage induced by resveratrol (Fig.1B) 
resveratrol effect on Det562 cell viability (Fig. 1A) , suggesting that the observed decrease in cell viability by resveratrol in FaDu and Cal27 cells is possibly due to its DNA damage inducing effect.
Importantly, DNA damage was not observed in normal cells (NHEK and HFF) even at higher dose of resveratrol (Fig. 1C) , showing it's selectivity towards HNSCC cells. In Fig. 1C , NHEK cells in the treatment groups are added less in number purposely to see the comet tail. Thus, cells are more in the control group as compared to resveratrol treated group. Further, we have found that resveratrol had no effect on the cell growth and cell number (data not shown) of NHEK cells.
Resveratrol selectively causes cell cycle arrest and apoptosis in HNSCC cells independent of
Smad4
Based on results in Fig. 1 showing resveratrol-caused decreased cell viability and DNA damage selectively in HNSCC cells carrying non-functional Smad4 (FaDu and Cal27), next we assessed its effect on cell cycle progression and apoptosis in FaDu cells (deletion Smad4) and Cal27-Smad4 cells over expressing Smad4 ( Fig. 2A ) in order to address whether a lack of resveratrol effect in Det562 cells is due to their wild type Smad4 status. Resveratrol (10 μM) arrested FaDu cells in S phase (66%, p<0.001) compared to controls with 34% S-phase population (Fig. 2B) ; however, higher resveratrol concentrations (25-50 μM) for 24 h caused G1 arrest (63-78%) compared to control (41%; Fig. 2B ). Regarding Cal27, compared to controls with 38-39% cells in S phase, resveratrol (25 μM) significantly induced S-phase arrest (53 and 56%; p<0.001) in both vector control Cal27-pcDNA3 and Smad4 over expressing (based on over expressed Smad4 protein, Fig.2A ) Cal27-Smad4 cells, respectively (Fig. 2C) . These findings revealed that resveratrol efficacy in Cal27 and a lack of efficacy in Det562 cells are independent of Smad4 expression. In other studies, resveratrol (50-100 μM) treatments did not alter cell cycle progression in NHEK cells ( (Fig. 3) . Similar to S phase arrest results, Cal27 cells with overexpression of Smad4 retained sensitivity to resveratrol-induced apoptosis (Fig. 3C) , suggesting that the effect on apoptosis is also independent of Smad4.
Resveratrol induces γH2AX and Brca1 foci formation in HNSCC cells
H2AX ser-139 phosphorylation (so-called γH2AX) is essential for recruiting and localizing DNA repair proteins (Brca1 and Rad51) at the sites containing damaged chromatin and for checkpoint activation which arrest cell cycle progression (16) . Brca1 is a tumor suppressor protein involved in maintaining genome integrity, and following DNA damage, it accumulates in nucleus, where it concentrates in nuclear foci with other DNA double strand breaks (DSBs) repair factors including homologous recombination protein, RAD51, and end-joining RAD50-MRE11-NBS1 protein complex (17) . Accordingly, to further dissect resveratrol mechanism of action, we assessed γH2AX and Brca1 foci formation. Resveratrol enhanced γH2AX levels in both FaDu and Cal27, but had no effect in Det562 cells. A higher resveratrol dose (100 μM) also induced γH2AX in NHEK but to a lesser extent in FaDu and Cal27 cells (Fig. 4A) . We also compared γH2AX levels in parental Cal27 versus two independently derived Cal27-Smad4 cells (generated by us and the Wang lab (8) and found them to be comparable among these lines. Together, these results clearly indicated that resveratrol triggered DNA damage in HNSCC cells independent of Smad4 expression. Consistently, compared to controls, resveratrol also induced discrete nuclear γH2AX and Brca1 foci formation in FaDu cells where Brca1 co-localized with γH2AX at the sites of DNA damage (Fig. 4B) . Another important observation related to DNA damaging effect of resveratrol in FaDu cells is an S phase arrest at 10 μM but a G1 phase arrest at higher concentration (25-50 μM) ( Fig. 2A) , and a higher γH2AX levels with increasing resveratrol concentration indicative of increasing levels of DNA damage (Fig. 4A) , which is consistent with G1 or G1/S arrest at higher concentrations. Accordingly, we also determined cyclin levels in FaDu cells after resveratrol treatment and found that whereas cyclin D1 levels decreased, cyclin E levels increased (data not shown) simultaneously, a situation representing inhibition of DNA replication and a concomitant G1/S arrest and blockade to S phase progression by resveratrol as we had seen in ovarian cancer cells (9) .
Resveratrol-induced γH2AX and Brca1 foci formation is independent of Smad4 in
Cal27 cells
Recently, Smad4 loss was reported to cause genomic instability in mice, which correlated with less expression and function of genes encoding proteins in the Brca/Fanc in DNA repair pathway together with HNSCC development (8) . Thus, we measured γH2AX and Brca1 foci formation in Cal27-pcDNA3 and Cal27-Smad4 cells. Cal27-pcDNA3 and Cal27-Smad4 cells showed almost parallel γH2AX foci formation after resveratrol (50 μM) treatment for 24 h (Fig. 5A ). Mitomycin (20 ng/ml; MMC) treatment also induced the γH2AX foci formation in both the cell lines (Fig. 5A) .
However, MMC treated cells displayed less intense staining as compared to resveratrol treated cells (Fig. 5A ). Brca1 staining was also examined in both cell lines after resveratrol treatment.
Resveratrol (50 μM) treatment for 24 h induced strong nuclear localization of Brca1 as compared to untreated control (Fig. 5B) . However, Cal27-Smad4 control cells showed similar Brca1 foci formation as compared to Cal27-pcDNA3 control cells (Fig. 5B) . As shown previously (8) was required for the formation of Brca1 foci by MMC (Fig. 5B) . Thus, unlike MMC, resveratrol can produce Brca1 foci independently of Smad4.
Resveratrol inhibits FaDu tumor xenograft growth together with in vivo DNA-damage and apoptotic effects
We also extended studies to an in vivo xenograft model to establish biological significance of all our in vitro findings. Resveratrol feeding by oral gavage resulted in a dose-and time-dependent inhibition in tumor growth, and at the end of the study (30 days), tumor volume/mouse decreased from 2.00 ± 0.25 in controls to 1.35 ± 0.12 and 1.01 ± 0.17 cm 3 in 10 and 50 mg/kg body weight resveratrol-fed groups, respectively, accounting for 32 and 50% (p<0.01) inhibition in tumor growth (Fig. 6A) . A reduction in tumor weight/mouse further supported these results where resveratroltreated groups showed 0.95 ± 0.15 and 0.76 ± 0.13 g/mouse tumor weight, respectively, as compared to controls with 2.00 ± 0.35 g/mouse tumor weight (Fig. 6A) . In contrast, resveratrol (50 mg/kg body weight) feeding for 15 days had less of an effect that was not statistically significant (Fig. 6A) . In both efficacy studies, compared to controls, we did not observe any significant changes in body weight and diet consumption in resveratrol-fed groups of mice throughout the experiments (data not shown), suggesting that the resveratrol doses and treatment regimens employed in this study are non-toxic.
The qualitative γH2AX and cleaved caspase-3 IHC analyses of tumor xenografts for DNA damage and apoptosis markers, respectively, clearly showed a strong increase in both staining in resveratrol-treated tumors compared to controls (Fig. 6B ), Quantitative nuclear γH2AX
immunostaining showed 25% (p<0.001) and 32% (p<0.001) induction in FaDu tumor xenografts from 10 and 50 mg/kg body weight resveratrol-treated mice, respectively, compared to 13% in (Fig. 6B, upper panel) . Similarly, cleaved caspase-3 staining also increased 11-16% (p<0.001) in FaDu tumor xenografts from resveratrol-treated mice compared to 5 % cells in controls (Fig. 6B, lower panel) .
Discussion
Following DNA damage, normal cells either repair the damage or undergo apoptotic death mostly in p53-dependent manner. However, DNA repair processes are defective in many cancer cells (18) which offer avenues for therapeutic intervention. Consequently, the present study is highly significant with major therapeutic implications in that the anti-cancer effect of resveratrol is predominately due to its ability to induce DNA damage selectively in HNSCC cells without affecting normal, repair-proficient cells.
Our detailed mechanistic studies revealed that resveratrol-induced DNA damage in HNSCC cells results in DNA strand breaks as evident by the production of Comet tails and 'defective' γH2AX and Brca1 repair foci resulting in irreversible arrest of HNSCC cells either at the G1/S phase boundary or in S phase eventually leading to apoptotic death. Similar results have been seen in breast cancer cells lacking Brca2 (19) and in colon cancer cells lacking Cdc14 (20) in which foci form after DNA damage but are repaired inefficiently. Since p53 is important for DNA repair mechanisms, the novelty of our study is that resveratrol effects were independent of p53 because all three HNSCC cell lines used harbor mutant p53 mutations (21) . Furthermore, sensitivity to resveratrol was directly proportional to extent of basal DNA damage. For example, FaDu cells having higher level of basal DNA damage (Fig. 1B) were more sensitive to resveratrol than Cal27 cells (Fig. 1A) . Similarly, Det562 cells with no detectable γH2AX even in 50 μM resveratrol were comparatively more resistant to treatment than the other two HNSCC cell lines. Because and a marked induction in apoptosis . Overall, our results clearly demonstrate strong resveratrol efficacy against the growth and proliferation of HNSCC in vitro and in vivo. Specifically, resveratrol produces these effects on HNSCC via its selective ability to induce DNA damage and apoptotic death. Importantly, the anti-cancer effects of resveratrol and all associated mechanisms are independent of Smad4 status, the mutation /absence of which is one of the primary causes of failed cellular DNA repair machinery in HNSCC. Based on these findings, more studies are needed in future to evaluate both anti-cancer and chemopreventive efficacy of resveratrol in relevant preclinical models to establish its potential usefulness against human HNSCC. 
